Head-to-head evidence
monlunabant vs nimacimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: CB1 receptor · full Obesity pipeline
monlunabant
Developed by Novo Nordisk
NCT06542536 · Phase 1 · completed
The study was randomized and blinded against placebo, but it was conducted in healthy volunteers rather than people with obesity, and its purpose was pharmacokinetic bridging and safety, not proving a clinical effect. No results have been posted.
nimacimab
Developed by Skye Bioscience
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06577090 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: monlunabant's landscape · nimacimab's landscape